# A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

> **NCT02147431** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 38 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** semaglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02147431
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-21
- **Primary completion:** 2015-05-20
- **Final completion:** 2015-05-20
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02147431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02147431, "A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02147431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*